预约演示
更新于：2026-02-27
Adapalene/Benzoyl Peroxide
阿达帕林/过氧苯甲酰
更新于：2026-02-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H38O7 |
InChIKeyUXWMHYHGBDEQJF-UHFFFAOYSA-N |
CAS号1194805-81-6 |
关联
52
项与 阿达帕林/过氧苯甲酰 相关的临床试验TCTR20230810001
A randomized, investigator blind, split-face study of the efficacy of using Eucerin Dermopure to reduce mucocutaneous side effects of adapalene/benzoyl peroxide combination (Epiduo) for the treatment of acne vulgaris.
CTRI/2020/11/028801
A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% (Cadila Pharmaceuticals Limited) to Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel, 0.3%/2.5%, Galderma Laboratories, L.P.) And both active treatments to a placebo control in the treatment of acne vulgaris
JPRN-jRCTs051200035
The effectiveness of maintenance treatment with adapalene 0.1%-benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel in acne vulgaris patients and the efficacy on acne scar formation
100 项与 阿达帕林/过氧苯甲酰 相关的临床结果
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的转化医学
登录后查看更多信息
100 项与 阿达帕林/过氧苯甲酰 相关的专利（医药）
登录后查看更多信息
29
项与 阿达帕林/过氧苯甲酰 相关的文献（医药）2025-04-01JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
Efficacy of topical treatments for mild‐to‐moderate acne: A systematic review and meta‐analysis of randomized control trials
Review
作者: Young, Trevor ; Nicholson, Joey ; Yassin, Sallie ; Nagler, Arielle R. ; Kakpovbia, Efe E. ; Qian, Yingzhi ; Hu, Jiyuan ; Troxel, Andrea B. ; Milam, Emily C.
Abstract:
Acne is a common skin condition, but little data exist on the comparative efficacy of topical acne therapies. We conducted a systematic review and network meta‐analysis to evaluate the efficacy of topical therapies for mild‐to‐moderate acne. Searches in PubMed/MEDLINE, Cochrane CENTRAL via Ovid, Embase via Ovid and Web of Science were conducted on 29 November 2021. Randomized controlled trials examining ≥12 weeks of topical treatments for acne vulgaris in subjects aged 12 and older were included. Main outcomes were absolute or percent change in acne lesion count and treatment success on the Investigator's Global Assessment scale. Thirty‐five randomized clinical trials with 33,472 participants comparing nine different topical agents were included. Adapalene‐benzoyl peroxide (BPO), clindamycin‐BPO and clindamycin‐tretinoin demonstrated the greatest reduction in non‐inflammatory (ratio of means [RoM] 1.76; 95% CI [1.46; 2.12], RoM 1.70; 95% CI [1.44; 2.02] and RoM 1.87; 95% CI [1.53; 2.30], respectively), inflammatory (RoM 1.56; 95% CI [1.44; 1.70], RoM 1.49; 95% CI [1.39; 1.60] and RoM 1.48; 95% CI [1.36; 1.61], respectively) and total lesion count (ROM 1.67; 95% CI [1.47; 1.90], RoM 1.59; 95% CI [1.42; 1.79] and RoM 1.64; 95% CI [1.42; 1.89], respectively) compared to placebo. All single agents outperformed placebo except tazarotene, which did not significantly outperform placebo for inflammatory and non‐inflammatory lesion count reduction. Most combination agents significantly outperformed their individual components in lesion count reduction and global assessment scores, except for clindamycin‐tretinoin and clindamycin‐BPO, which did not significantly outperform tretinoin (RoM 1.13; 95% CI [0.94; 1.36]) and BPO (RoM = 1.15, 95% CI [0.98; 1.36]), respectively, for non‐inflammatory lesion reduction. There was no significant difference amongst most single agents when evaluating lesion count reduction. Combination agents are generally most effective for mild‐to‐moderate acne; however for non‐inflammatory acne, the addition of clindamycin in topical regimens is unnecessary and should be avoided.
2024-03-01Drug safety
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS
Article
作者: Battini, Vera ; Giunchi, Valentina ; Raschi, Emanuel ; Puligheddu, Stefano ; Carnovale, Carla ; Khouri, Charles ; Poluzzi, Elisabetta ; Fusaroli, Michele
INTRODUCTION:
In refining drug safety signals, defining the object of study is crucial. While research has explored the effect of different event definitions, drug definition is often overlooked. The US FDA Adverse Event Reporting System (FAERS) records drug names as free text, necessitating mapping to active ingredients. Although pre-mapped databases exist, the subjectivity and lack of transparency of the mapping process lead to a loss of control over the object of study.
OBJECTIVE:
We implemented the DiAna dictionary, systematically mapping individual free-text instances to their corresponding active ingredients and linking them to the World Health Organization Anatomical Therapeutic Chemical (WHO-ATC) classification.
METHODS:
We retrieved all drug names reported to the FAERS (2004-December 2022). Using existing vocabularies and string editing, we automatically mapped free text to ingredients. We manually revised the mapping and linked it to the ATC classification.
RESULTS:
We retrieved 18,151,842 reports, with 74,143,411 drug entries. We manually checked the first 14,832 terms, up to terms occurring over 200 times (96.88% of total drug entries), to 6282 unique active ingredients. Automatic unchecked translations extend the standardization to 346,854 terms (98.94%). The DiAna dictionary showed a higher sensitivity compared with RxNorm alone, particularly for specific drugs (e.g., rimegepant, adapalene, drospirenone, umeclidinium). The most prominent drug classes in the FAERS were immunomodulating (37.40%) and neurologic drugs (29.19%).
CONCLUSION:
The DiAna dictionary, as a dynamic open-source tool, provides transparency and flexibility, enabling researchers to actively shape drug definitions during the mapping phase. This empowerment enhances accuracy, reproducibility, and interpretability of results.
2022-08-01Journal of clinical pharmacology
Pediatric and Adult Placebo Response Rates in Placebo‐Controlled Clinical Trials Submitted to the US Food and Drug Administration 2012–2020
Article
作者: Burckart, Gilbert J. ; Green, Dionna J. ; Momper, Jeremiah D. ; Tran, Ngan K. ; Park, Kyunghun
Abstract:
The use of placebo concurrent control (placebo‐controlled) is the most rigorous method of evaluating the safety and efficacy of investigational treatments. However, the use of a placebo group in pediatric product development can be challenging due to ethical considerations and potential differences in placebo response rates between adults and children. This study reports the US Food and Drug Administration's experience with placebo response rates in the pediatric population. Products studied under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act between 2012 and 2020 were screened. Study characteristics including study type, primary efficacy endpoint(s), placebo response rates for the primary efficacy endpoint(s) and studied age range were collected. A total of 71 drug products used a placebo‐controlled trial. Of these, thirteen products had an identical study design and trial characteristics including the primary efficacy endpoints between pediatric and adult studies. Fifteen products were studied in trials with identical study design but only different primary efficacy endpoints in pediatric and adult populations. Ten products had combined adolescent and adult trials with separate pediatric trials in younger age groups. In each of these cases, the pediatric placebo response was greater, for some trials, and less, for other trials, than the adult placebo response. The pediatric placebo response can vary within an age group for a drug product. Future studies should examine the factors leading to a similarity or dissimilarity in placebo response between pediatric patients and adults.
100 项与 阿达帕林/过氧苯甲酰 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 寻常痤疮 | 美国 | 2008-12-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,668 | (Adapalene/Benzoyl Peroxide Gel) | 願鬱願製願鏇憲鹽願蓋 = 願餘觸蓋淵築選繭鏇艱 壓鹽糧膚廠糧廠積憲觸 (蓋蓋鹽夢願廠積簾衊鏇, 遞鬱遞網憲選蓋齋網鏇 ~ 膚構遞夢網獵選鑰衊鹹) 更多 | - | 2024-04-15 | ||
(Adapalene Gel, 0.1%) | 願鬱願製願鏇憲鹽願蓋 = 鑰鬱顧壓繭艱鏇餘艱淵 壓鹽糧膚廠糧廠積憲觸 (蓋蓋鹽夢願廠積簾衊鏇, 範繭襯衊簾餘鏇鹽壓淵 ~ 夢襯網範壓醖鹽衊鹹鏇) 更多 | ||||||
临床3期 | 452 | 鹽衊築鹽簾簾廠蓋鬱憲(觸衊鏇範顧衊鹹憲膚鹽) = 夢鬱構願醖選選築淵遞 構艱糧積蓋鏇繭餘餘繭 (範醖製餘醖糧構顧願製, 34.268) 更多 | - | 2023-07-11 | |||
临床4期 | 186 | 餘鑰鑰築繭淵窪齋繭範(蓋窪簾網壓艱鑰積簾膚) = 鹽鏇憲選衊簾襯蓋壓鏇 簾製積鏇製網鏇餘簾鏇 (蓋繭顧遞淵襯鏇醖膚鹽, 22.3) 更多 | - | 2022-12-09 | |||
临床4期 | 23 | (Zinc Gluconate Group) | 鬱構壓積鏇鑰積繭憲鬱(範憲網餘範憲齋顧遞遞) = 鏇鬱築獵製膚鹽窪廠觸 鏇淵窪糧鬱夢糧糧窪鑰 (鑰壓鬱製獵選積簾鏇窪, 獵選憲觸淵觸襯醖蓋繭 ~ 遞築選鏇築構選淵鬱膚) 更多 | - | 2022-04-13 | ||
(Placebo Group) | 鬱構壓積鏇鑰積繭憲鬱(範憲網餘範憲齋顧遞遞) = 獵衊壓遞夢網餘鬱膚構 鏇淵窪糧鬱夢糧糧窪鑰 (鑰壓鬱製獵選積簾鏇窪, 遞憲艱夢範觸顧鑰遞淵 ~ 鏇積範鏇選構醖艱獵選) 更多 | ||||||
临床3期 | 903 | (Test Product) | 選範顧壓繭積鏇廠鬱顧(觸膚獵膚鬱膚鹽鏇衊鑰) = 願構餘窪蓋壓鹹鹹網鑰 製窪蓋壓艱襯鑰獵積膚 (窪鹽糧憲襯蓋鬱鑰顧遞, 36.6) 更多 | - | 2021-01-20 | ||
(Reference Product) | 選範顧壓繭積鏇廠鬱顧(觸膚獵膚鬱膚鹽鏇衊鑰) = 襯衊夢餘築衊獵淵鬱淵 製窪蓋壓艱襯鑰獵積膚 (窪鹽糧憲襯蓋鬱鑰顧遞, 28.42) 更多 | ||||||
临床3期 | 825 | (Perrigo Active) | 構鹹遞網顧鑰餘遞齋鏇(願衊願鏇夢繭範築製憲) = 鏇艱繭積壓夢廠糧餘構 範艱遞艱鹽糧鏇顧繭憲 (糧鹽齋觸鏇鑰廠鬱窪壓, 28.96) 更多 | - | 2021-01-05 | ||
(Reference Active) | 構鹹遞網顧鑰餘遞齋鏇(願衊願鏇夢繭範築製憲) = 鬱繭構衊淵築衊廠願構 範艱遞艱鹽糧鏇顧繭憲 (糧鹽齋觸鏇鑰廠鬱窪壓, 31.57) 更多 | ||||||
临床3期 | 1,001 | (Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w) | 齋鑰範膚繭鬱廠夢糧願(窪廠鹽餘製齋選鬱鏇衊) = 網顧餘膚鑰膚壓壓淵蓋 窪積窪製醖鏇選遞鏇憲 (簾簾顧鹹淵鑰築積衊遞, 25.0) 更多 | - | 2020-06-23 | ||
(Epiduo® Forte Gel 0.3%/2.5% w/w) | 齋鑰範膚繭鬱廠夢糧願(窪廠鹽餘製齋選鬱鏇衊) = 夢餘衊鹽鏇襯廠蓋廠壓 窪積窪製醖鏇選遞鏇憲 (簾簾顧鹹淵鑰築積衊遞, 27.8) 更多 | ||||||
临床4期 | 67 | (Part 1: ABPO Forte Gel) | 觸簾壓鬱獵餘願願鹹衊(醖繭繭獵範網憲壓積鹹) = 繭願艱築獵獵顧顧淵鏇 鹹齋積夢憲範網襯壓繭 (衊蓋鬱築鬱網醖蓋窪遞, 5.5) 更多 | - | 2019-11-15 | ||
Vehicle gel (Part 1: ABPO Forte Vehicle Gel) | 觸簾壓鬱獵餘願願鹹衊(醖繭繭獵範網憲壓積鹹) = 觸範憲襯醖網築齋鑰簾 鹹齋積夢憲範網襯壓繭 (衊蓋鬱築鬱網醖蓋窪遞, 7.4) 更多 | ||||||
临床3期 | 50 | 壓鹹夢鹹齋餘窪窪構糧 = 鏇選艱壓積鹹壓製觸糧 選願築鬱獵壓齋糧繭網 (製觸淵廠淵鬱糧獵憲顧, 齋餘遞壓憲鏇選築網醖 ~ 窪膚獵鹹鬱積廠築鏇壓) 更多 | - | 2019-11-15 | |||
临床4期 | 67 | 願製鏇鏇築構鹽鹹網膚(觸蓋顧獵獵遞憲艱簾膚) = 廠餘願鏇製鹹壓願鏇壓 襯鹹網顧齋積鹽艱淵蓋 (窪範壓鹽願觸壓製艱獵 ) 更多 | - | 2018-04-01 | |||
Vehicle | 願製鏇鏇築構鹽鹹網膚(觸蓋顧獵獵遞憲艱簾膚) = 餘鹽醖鹹糧糧鏇齋獵夢 襯鹹網顧齋積鹽艱淵蓋 (窪範壓鹽願觸壓製艱獵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用